Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tisagenleucel

- PMLiVE

Novartis strengthens autoimmune indications for Cosentyx

Data shows its IL-17A inhibitor can reduce structural disease progression

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

Novartis moves swiftly with lymphoma filing for CAR-T Kymriah

Will go up against Kite Pharma's Yescarta if approved

- PMLiVE

Novartis to buy French radiopharma specialist AAA for $3.9bn

Deal will strengthen its cancer therapy business, says Swiss pharma group

Novartis Gehry Building

Alcon spin-out more likely but not imminent, says Novartis

A stand-alone company could offer “additional shareholder value”

- PMLiVE

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

Novartis looks outside pharma for digital transformation

Appoints former Sainsbury's Argos executive Bertrand Bodson

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

- PMLiVE

Cellectis floored by patient death in CAR-T trial

FDA puts two cancer immunotherapy trials on hold

- PMLiVE

Vas Narasimhan takes top Novartis job on Jimenez departure

The soon-to-be CEO will take over at a time when the company has a strong pipeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links